Shots:
- The MHRA has approved Cytokinetics’ Myqorzo (aficamten) for the treatment of adults with symptomatic (NYHA, class II-III) oHCM
- MHRA assessment was based on P-III (SEQUOIA-HCM) trial of Myqorzo (n=282), showing improved exercise capacity vs PBO at 24wks., with increased peak oxygen uptake by 1.8 vs 0 ml/kg/min
- Additionally, NICE has recommended aficamten for eligible adults with symptomatic oHCM (NYHA class II–III) in England & Wales as an add-on to optimized standard care or as monotherapy when standard treatments are contraindicated
Ref: Globenewswire | Image: Cytokinetics | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
